Industries / Health / Pharmaceuticals / Biotech
Cell and gene therapy
This work makes medicines that are living cells, or that add, fix or switch off a gene inside a patient's own cells.
7
Milestones achieved, from 1990 to 2025.
3
To watch for: announced, not yet confirmed outside.
3
Open deliverables. Nobody has shipped them.
The road
AchievedWatch forOpen
Achieved
1990
First approved gene therapy trial
On 14 September 1990, doctors at the US National Institutes of Health (NIH) took white blood cells from Ashanthi DeSilva, aged 4, who had ADA-SCID, an inherited immune disease. They used a retrovirus, a virus that writes its genes into the cell's DNA, to add a working ADA gene, then returned the cells to her. NIH said in 1995 that she and a second girl were "doing so well four years later". Both stayed on the standard enzyme drug, so the gene therapy was an add-on, not a cure.
Credit
R. Michael Blaese, W. French Anderson and NIH colleagues
1999
A death in a trial
Jesse Gelsinger died four days after an infusion in a University of Pennsylvania safety trial that used an altered cold virus (adenovirus) to carry a liver gene. Investigators found the researchers had not applied stricter entry rules as promised, had not reported serious side effects promptly, and had not given him adequate information before consent. In January 2000 the FDA suspended human research at Penn's gene therapy institute. The FDA and NIH then found that 691 gene therapy volunteers had died or fallen ill in the previous seven years, and only 39 of those cases had been reported promptly.
Lessonregulators tightened trial monitoring and inspections and set up a new system for reporting side effects.
Credit
FDA; Penn Institute for Human Gene Therapy (director James Wilson)
2008
The carrier caused leukaemia
In a Paris trial for X-linked SCID, another inherited immune disease, gene therapy corrected the disease in 9 of 10 children. Four of the 10 then developed T-cell leukaemia, 31 to 68 months after treatment. In three of the four, the virus had landed next to a cancer gene called LMO2 and switched it on. Chemotherapy cleared the leukaemia in three children; one died.
Lessonwhere a carrier virus inserts into DNA matters, and this pushed the field toward safer carriers and long follow-up.
Credit
Salima Hacein-Bey-Abina, Alain Fischer, Marina Cavazzana-Calvo, Hôpital Necker–Enfants Malades
2012
Approved, then not renewed
On 25 October 2012 the European Union authorised Glybera, a one-time gene therapy for a rare fat-processing disorder, lipoprotein lipase deficiency. The authorisation ended on 28 October 2017 because the maker, uniQure, did not apply to renew it, citing little demand.
Lessonan approved gene therapy can still fail if too few patients use it.
Credit
uniQure; European Medicines Agency (EMA)
2017
First US gene therapy approvals
On 30 August 2017 the FDA approved Novartis's Kymriah, which NPR reported the FDA calling the first gene therapy approved in the US. Kymriah is a CAR-T therapy: a patient's T cells, a kind of immune cell, are changed in a lab to attack leukaemia and infused back. In the trial, 83% of 63 young patients were in remission within three months, and the list price was USD 475,000. On 19 December 2017 the FDA approved Spark Therapeutics' Luxturna, in which a modified virus carries a healthy RPE65 gene straight into cells of the retina.
Credit
Novartis; Spark Therapeutics; FDA
2023
First licensed CRISPR medicine
On 15 November 2023 the UK regulator, the MHRA, authorised Casgevy for sickle-cell disease and beta-thalassaemia and called it the first licensed medicine that uses CRISPR. Doctors take a patient's bone-marrow stem cells, edit them in a lab and infuse them back. The FDA approved it on 8 December 2023. In the FDA's data, 29 of 31 evaluable patients (93.5%) had no severe pain crises for at least 12 months in a row.
Credit
Vertex Pharmaceuticals and CRISPR Therapeutics
2025
Use narrowed after deaths
On 14 November 2025 the FDA added a boxed warning, its strongest label warning, to Sarepta's Elevidys, a gene therapy for Duchenne muscular dystrophy, after two boys who could no longer walk died of acute liver failure. The FDA removed the use for patients who cannot walk, limited it to walking patients aged 4 and over, and required a study of about 200 patients with liver monitoring for at least 12 months.
Lessona gene therapy's safety record can change after approval, so patients have to be followed for years.
Credit
FDA; Sarepta Therapeutics
Watch for
Gene editing for one patient
A team at the Children's Hospital of Philadelphia (CHOP) and Penn designed a base editor, a CRISPR tool that changes a single DNA letter, for one baby, KJ Muldoon, who has CPS1 deficiency, a rare liver disease. They made the medicine in about six months and gave him three doses from February to April 2025, delivered to his liver in fat particles, with no serious side effects reported. CHOP calls him the world's first patient to get a personalised CRISPR therapy. A year on, CHOP said he eats more protein and needs less medicine, but that the treatment "isn't a cure".
Achieved whenother centres treat more patients with custom editors made the same way, in a registered trial, and publish results with long follow-up.
Claimed by
CHOP and Penn Medicine (Rebecca Ahrens-Nicklas, Kiran Musunuru), May 2025, with an update in 2026
CAR-T made inside the body
ESO-T01 is a gene carrier made from a disabled virus, infused straight into the blood to turn the patient's own T cells into CAR-T cells, with no cell harvesting, lab manufacturing or chemotherapy beforehand. A Wuhan team reported four multiple myeloma patients in The Lancet in July 2025. In a March 2026 report, all four patients who could be assessed had no detectable disease, all five patients had serious (grade 3 or worse) side effects, and one died of cardiac arrest 19 days after infusion, which the authors put down to his cancer. AstraZeneca bought the developer, EsoBiotec, for USD 425 million upfront.
Achieved whenlarger trials at several centres reproduce the responses with acceptable safety, or a regulator approves an in-body CAR-T.
Claimed by
Heng Mei's team in Wuhan, with EsoBiotec and AstraZeneca, July 2025 and March 2026
Approval on how a drug works
On 23 February 2026 the FDA issued draft guidance for a "plausible mechanism" framework, for custom gene-editing and RNA drugs made for diseases too rare for randomised trials. It sets five tests: the faulty gene is known, the drug targets that cause, the course of untreated disease is well recorded, the edit is shown to have worked, and patients improve. CHOP says good results in as few as 5 to 10 patients could support approval of a whole platform.
Achieved whenthe guidance is final and at least one product is approved through it.
Claimed by
FDA, February 2026
Open
01
A register of approved therapies
A free, downloadable table with one row per cell or gene therapy product. Each row gives the approval date from each regulator (FDA, EMA, MHRA, Japan, China, South Korea), the published list price where there is one, withdrawals and expiries, and safety actions such as boxed warnings or narrowed uses. Every field links to its source.
The briefCredit · unclaimed02
Tag manufacturing problems in reviews
A dataset built from the FDA's posted review documents for cell and gene therapies, such as each product's Summary Basis for Regulatory Action and its complete response letters, the letters the FDA sends when it refuses an application. Every manufacturing and quality issue is tagged by type (potency test, sterility, stability, inspection, starting material) with a page reference.
The briefCredit · unclaimed03
Track long-term follow-up studies
A page with one row per approved product listing its long-term follow-up studies, which check treated patients for late harms, sometimes for 15 years. Each row shows the registry ID, planned end date, enrolment, whether results are posted and linked papers, and the page refreshes monthly.
The briefCredit · unclaimed
Open 01 · the brief
A register of approved therapies
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A free, downloadable table with one row per cell or gene therapy product. Each row gives the approval date from each regulator (FDA, EMA, MHRA, Japan, China, South Korea), the published list price where there is one, withdrawals and expiries, and safety actions such as boxed warnings or narrowed uses. Every field links to its source.
Why it is still open
The FDA's own list, current as of 30 October 2026, has 55 entries with no prices, no other regulators' dates, no safety actions and no download. The ASGCT and Citeline quarterly report counts 45 approved gene therapies worldwide (second quarter of 2026), but its figures come from paid databases. A 2026 ISPOR poster compared FDA and EMA approvals by hand, without prices or safety actions, and does not say it released a dataset.
Built with what exists
Python (requests, BeautifulSoup) to collect FDA and EMA product pages; pdftotext for approval letters; a CSV file in a public GitHub repository with a change log.
First step
Enter the 55 FDA entries and the EMA pages for the same products into a draft CSV, using Glybera's EMA page as the pattern for a withdrawal, with a source link in every column.
Done looks like
Every FDA-listed product and every EMA-authorised gene therapy is in the table with at least one approval date and a working source link, and a second person's check of 30 random fields finds at least 95% match their sources.
Open 02 · the brief
Tag manufacturing problems in reviews
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A dataset built from the FDA's posted review documents for cell and gene therapies, such as each product's Summary Basis for Regulatory Action and its complete response letters, the letters the FDA sends when it refuses an application. Every manufacturing and quality issue is tagged by type (potency test, sterility, stability, inspection, starting material) with a page reference.
Why it is still open
An October 2026 analysis of 426 letters in the openFDA set of complete response letters says "there is no active categorization of CMC-related decisions" (CMC means chemistry, manufacturing and controls); its author relied on keyword search and called the roughly 75% CMC share an estimate. The FDA posts each product's reviews as separate files.
Built with what exists
The openFDA complete response letter dataset; FDA product pages; pdftotext; a large language model such as Claude to suggest tags, with a person checking each one. The note "Seven more flagged" (Claude at Enveda) covers a model reviewing drug-making records for issues, a similar task.
First step
Download the Summary Basis documents for Kymriah, Luxturna, Casgevy, Elevidys and one more product, and write a six-category tagging guide.
Done looks like
Every Summary Basis document for FDA-listed gene therapies parsed, every tag citing a page, and agreement of at least 90% with a person's labels on a hand-labelled sample of 50 passages.
Open 03 · the brief
Track long-term follow-up studies
The first to publish is credited on this line, and the deliverable moves from Open to Achieved.
What to build
A page with one row per approved product listing its long-term follow-up studies, which check treated patients for late harms, sometimes for 15 years. Each row shows the registry ID, planned end date, enrolment, whether results are posted and linked papers, and the page refreshes monthly.
Why it is still open
FDA guidance from January 2020 recommends 15 years of follow-up for carriers that write into DNA, such as lentiviruses, and up to 15 years for gene-editing products. It says follow-up data gathered after approval go into the company's annual report to the FDA, which is not public.
Built with what exists
The ClinicalTrials.gov API (version 2), the ISRCTN and EU trial registries, the FDA approved-products list, and a scheduled script (for example on GitHub Actions) that writes a static web page.
First step
Search ClinicalTrials.gov for "long-term follow-up" with each product name on the FDA list, and save the matches with their result status.
Done looks like
Every FDA-listed product that uses a DNA-inserting carrier or gene editing is linked to at least one follow-up study or marked "none found", the share of studies with posted results is reported, and the page has refreshed on schedule for 3 months in a row.